Vanguard Global Advisers
CRNX icon

Vanguard Global Advisers’s Crinetics Pharmaceuticals CRNX Stock Holding History

Vanguard Global Advisers’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.49M Sell
39,711
-1,046
-3% -$38.9K ﹤0.01% 1478
2026
Q1 		$1.48M Buy
+40,757
New +$1.82M ﹤0.01% 1400

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Global Advisers's CRNX Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Crinetics Pharmaceuticals (CRNX) stake by 2.6% in Q2 2026, selling an estimated $38.9K and leaving 39,711 shares worth $1.49M. The position accounts for ﹤0.01% of the portfolio, ranked #1478.

Vanguard Global Advisers first reported a position in CRNX in Q1 2026 and has held it in 2 quarters since. 265 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Vanguard Global Advisers held 39,711 shares of Crinetics Pharmaceuticals worth $1.49M as of Q2 2026.
  • Vanguard Global Advisers sold 1,046 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $38.9K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1478 holding.
  • Vanguard Global Advisers first reported a position in Crinetics Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 265 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.